Table 3.
Univariate effect of the non-weighted average CsA level between day 0 and day +14 post-transplantation.
| Outcomes | N | Day 100 Incidence (95% CI) | P – test for trend |
|---|---|---|---|
| GRADE II–IV acute GVHD | |||
| Average cyclosporine A level in ng/mL | |||
| <200 | 26 | 51% (40–62%) | 0.04 |
| 200–249 | 62 | 47% (34–60%) | |
| 250–249 | 93 | 47% (36–58%) | |
| 300–349 | 91 | 47% (36–58%) | |
| 350+ | 65 | 35% (25–45%) | |
| NON-RELAPSE MORTALITY | |||
| Average cyclosporine A level in ng/mL | |||
| <200 | 26 | 40% (20–60%) | 0.02 |
| 200–249 | 62 | 36% (23–49%) | |
| 250–249 | 93 | 25% (15–35%) | |
| 300–349 | 91 | 25% (15–35%) | |
| 350+ | 65 | 22% (13–31%) | |
| OVERALL SURVIVAL | |||
| Average cyclosporine A level in ng/mL | |||
| <200 | 26 | 38% (19–57%) | 0.07 |
| 200–249 | 62 | 37% (24–51%) | |
| 250–249 | 93 | 46% (33–59%) | |
| 300–349 | 91 | 35% (23–47%) | |
| 350+ | 65 | 46% (31–61%) | |
GVHD, graft-versus-host disease.